Ed Ho

Have a great noninvasive product to deal with heart problems. Have a new products in the pipeline. Good potential, but may be fully valued.

Not really happy with management. Took a big drop and is an interesting buy now. The drug works. Potential of being in phase three next year. Really cheap.

Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline.

Have about $11/12 million in cash and $23/24 million in sales. Profitable. Trading at half X sales. Cheap. Good management.

Have put in new (better) management and have recapitalized the costs.

Disappointed on their 2nd quarter, but they were building and shipping inventory in the first two quarters so results won't show until the 3rd/4th quarters.

Incredibly good management. Expects them to do $.10/$.12 in earnings this year.

Has a great product. Had some accounting issues. Expects they will succeed in the long term. Have to start showing sales. A " show me" company.

Has an interesting pipeline of products. An early stage product is a diabetes treatment.

Management has done a great job in bringing this company back from the dead. Not sure how much they can grow. Probably fairly valued.

An exceptionally well-run company. Relative to the other printers, it is an expensive stock. Good track record deserves a premium, but prefers a pure cyclical play.

Have a good technology and a well-run company. The question is, when do they get approval in the US for their commercialization of their ultraviolet scope.

Have proven up 2,000,000 tons of rock which, at $300 a ton makes it a low risk exploration play. Cheap.

Have had problems doing commercial production of silk fibers.

Trying to raise finances to move into the US market which could be risky. Fairly valued.